AVTX · Avalo Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | - | - | - | $249.0K | $0 | $0 | - |
| Cost of Revenue | - | - | - | $0 | - | - | ($714.0K) | $343.0K | ($80.0K) | - |
| Gross Profit | - | - | - | - | - | - | $963.0K | ($343.0K) | $80.0K | - |
| R&D | $14.05M | - | $13.62M | $14.07M | $9.12M | - | $9.54M | $4.60M | $2.12M | - |
| SG&A | $6.85M | - | $5.58M | $5.24M | $5.55M | - | $4.29M | $4.53M | $3.19M | - |
| Total Operating Expenses | $20.90M | - | $19.20M | $19.32M | $14.67M | - | $13.11M | $9.57M | $32.77M | - |
| D&A | $17.0K | - | - | - | $135.0K | - | - | - | $34.0K | - |
| Operating Income | ($20.90M) | - | ($19.20M) | ($19.32M) | ($14.67M) | - | ($12.86M) | ($9.57M) | ($32.77M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $12.0K | - | $11.0K | $16.0K | $8.0K | - | ($14.0K) | $7.0K | $7.0K | - |
| Net Income | ($19.63M) | - | ($30.63M) | ($20.77M) | ($13.15M) | - | $23.04M | $98.46M | ($121.29M) | - |
| EPS - Basic | ($0.98) | - | ($2.19) | ($1.92) | ($1.25) | - | $0.98 | $4.21 | ($141.00) | - |
| EPS - Diluted | ($0.98) | - | ($2.19) | ($1.92) | ($1.25) | - | ($2.83) | ($14.07) | ($141.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.99M | $15.86M | $26.96M | $42.29M | $125.05M | $134.55M | $81.86M | $93.43M | $110.18M | $7.42M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | $0 |
| Accounts Payable | $356.0K | $137.0K | $474.0K | $2.37M | $681.0K | $283.0K | $1.81M | $654.0K | $916.0K | $446.0K |
| Current Assets | $88.83M | $105.29M | $113.85M | $115.19M | $126.94M | $138.89M | $86.15M | $95.89M | $111.21M | $8.39M |
| Total Assets | $99.89M | $116.46M | $125.10M | $126.58M | $138.52M | $150.73M | $98.45M | $108.31M | $123.73M | $20.99M |
| Current Liabilities | $11.60M | $12.94M | $7.97M | $9.26M | $5.62M | $6.96M | $60.67M | $96.40M | $215.70M | $4.62M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $31.57M | $33.41M | $33.55M | $22.01M | $15.91M | $17.70M | $75.72M | $110.46M | $224.81M | $13.69M |
| Stockholders' Equity | $68.32M | $83.05M | $91.55M | $104.57M | $122.61M | $133.03M | $21.08M | ($13.61M) | ($112.54M) | $7.30M |
| Retained Earnings | ($468.15M) | ($448.52M) | ($434.80M) | ($404.18M) | ($383.41M) | ($370.26M) | ($334.92M) | ($357.96M) | ($456.42M) | ($335.13M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($17.69M) | - | - | - | ($9.46M) | - | - | - | ($6.20M) | - |
| Investing Cash Flow | $25.50M | - | - | - | $0 | - | - | - | $356.0K | - |
| Financing Cash Flow | $1.40M | - | - | - | $0 | - | - | - | $108.61M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | 386.7% | - | - | - |
| Operating margin | - | - | - | - | - | - | -5165.1% | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | 9251.8% | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | 3830.5% | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | 1721.3% | - | - | - |
| Effective tax rate | - | - | - | - | - | - | -0.1% | 0.0% | - | - |
| Return on assets | -19.7% | - | -24.5% | -16.4% | -9.5% | - | 23.4% | 90.9% | -98.0% | - |
| Return on equity | -28.7% | - | -33.5% | -19.9% | -10.7% | - | 109.3% | -723.6% | 107.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.66 | 8.14 | 14.28 | 12.44 | 22.61 | 19.96 | 1.42 | 0.99 | 0.52 | 1.82 |
| Quick ratio | 7.66 | 8.14 | 14.28 | 12.44 | 22.61 | 19.96 | 1.42 | 0.99 | 0.52 | 1.82 |
| Cash ratio | 2.15 | 1.23 | 3.38 | 4.57 | 22.27 | 19.33 | 1.35 | 0.97 | 0.51 | 1.61 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.46 | 1.40 | 1.37 | 1.21 | 1.13 | 1.13 | 4.67 | -7.96 | -1.10 | 2.87 |
| Liabilities / Assets | 0.32 | 0.29 | 0.27 | 0.17 | 0.11 | 0.12 | 0.77 | 1.02 | 1.82 | 0.65 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.00 | - | - | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | -926d | 696d | -4179d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 4.4x | - | 1.9x | 0.5x | 0.1x | - | 4.9x | - | - | - |
| P / S | - | - | - | - | - | - | 411.4x | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | -100.0% | - | - | - | 5.5% | -100.0% | -100.0% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | -43.1% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | -46.4% | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | -427.7% | - | - |
| Operating income growth (YoY) | -42.5% | - | -49.3% | -101.7% | 55.2% | - | -243.0% | -33.9% | -272.7% | - |
| Net income growth (YoY) | -49.3% | - | - | - | 89.2% | - | - | - | -1118.4% | - |
| EPS growth (YoY) | 21.6% | - | 22.6% | 86.4% | 99.1% | - | - | -919.6% | -5900.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -44.3% | -37.6% | 334.4% | - | - | 1721.4% | 43.4% | -95.3% | -1695.8% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$59.0K totalProduct$59.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Avalo Therapeutics against the 5 most active filers in the same SIC group.